Literature DB >> 14768001

Chronic liver disease mortality in the United States, 1990-1998.

Sirenda Vong1, Beth P Bell.   

Abstract

In 1998, chronic liver disease (CLD) was the tenth leading cause of death in the U.S. Alcohol and hepatitis C are thought to be important etiologies. However, traditional methods for calculating CLD mortality rates from death certificates may underestimate hepatitis C-related CLD mortality. We studied patterns of CLD deaths reported from 1990 through 1998, using an expanded definition that included death certificates where CLD, viral hepatitis, or CLD-related sequelae were reported as the underlying cause. We calculated overall age-specific and age-adjusted mortality rates, and according to demographic characteristics and recorded causes, and evaluated trends using linear regression modeling. CLD mortality declined 5% overall from 1990 through 1994 (12.1 to 11.6/100,000; P = 0.002), but remained unchanged from 1995 through 1998 (P = 0.366). Decreases were similar for all causes except hepatitis C, for which rates increased 220% from 1993 to 1998 (0.57 to 1.67/100,000). Rates declined in all racial-ethnic groups except American Indians and Alaska Natives (AI/AN), among whom rates were unchanged. Of 30,933 CLD deaths in 1998, 39% were coded as alcohol related, 15% as hepatitis C, 4% as hepatitis B, and 44% had no recorded cause. Age-adjusted rates were higher among males (47.6/100,000) than females (32.2/100,000) and among Hispanics (19.1/100,000) compared with non-Hispanics (10.8/100,000). Rates among AI/AN (28.7/100,000) were more than twice those of African Americans and whites (12.9/100,000 and 11.5/100,000, respectively). In conclusion, 1998 CLD deaths and the proportion attributable to viral hepatitis increased by 23% and 19%, respectively, compared with traditional methods. Mortality declines of the early 1990s were not sustained after 1994. Large disparities in CLD mortality remain, particularly among American Indians and Alaska Natives.

Entities:  

Mesh:

Year:  2004        PMID: 14768001     DOI: 10.1002/hep.20049

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  53 in total

Review 1.  Acute-on-chronic liver failure: what are the implications?

Authors:  Jody C Olson; Patrick S Kamath
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 2.  An analysis of content in comprehensive cancer control plans that address chronic hepatitis B and C virus infections as major risk factors for liver cancer.

Authors:  Behnoosh Momin; Lisa Richardson
Journal:  J Community Health       Date:  2012-08

3.  Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.

Authors:  Vinod Kumar; Naoya Kato; Yuji Urabe; Atsushi Takahashi; Ryosuke Muroyama; Naoya Hosono; Motoyuki Otsuka; Ryosuke Tateishi; Masao Omata; Hidewaki Nakagawa; Kazuhiko Koike; Naoyuki Kamatani; Michiaki Kubo; Yusuke Nakamura; Koichi Matsuda
Journal:  Nat Genet       Date:  2011-04-17       Impact factor: 38.330

4.  Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.

Authors:  David Widjaja; Suresh Yarlagadda; Bheema S Singu; Raghu S Loganathan; Steve Blum; Alan Bloom; Prospere Remy
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

5.  Race/ethnicity is associated with ABO-nonidentical liver transplantation in the United States.

Authors:  Jin Ge; John P Roberts; Jennifer C Lai
Journal:  Clin Transplant       Date:  2017-06-19       Impact factor: 2.863

Review 6.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

7.  Underestimation of liver-related mortality in the United States.

Authors:  Sumeet K Asrani; Joseph J Larson; Barbara Yawn; Terry M Therneau; W Ray Kim
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

8.  Complementary and alternative medicine use in chronic liver disease patients.

Authors:  Leah M Ferrucci; Beth P Bell; Kathy B Dhotre; M Michele Manos; Norah A Terrault; Atif Zaman; Rosemary C Murphy; Grace R Vanness; Ann R Thomas; Stephanie R Bialek; Mayur M Desai; Andre N Sofair
Journal:  J Clin Gastroenterol       Date:  2010-02       Impact factor: 3.062

9.  T2 relaxation time is related to liver fibrosis severity.

Authors:  Alexander R Guimaraes; Luiz Siqueira; Ritika Uppal; Jamu Alford; Bryan C Fuchs; Suguru Yamada; Kenneth Tanabe; Raymond T Chung; Gregory Lauwers; Michael L Chew; Giles W Boland; Duhyant V Sahani; Mark Vangel; Peter F Hahn; Peter Caravan
Journal:  Quant Imaging Med Surg       Date:  2016-04

10.  HCV-related mortality among male prison inmates in Texas, 1994-2003.

Authors:  Amy J Harzke; Jacques G Baillargeon; Michael F Kelley; Pamela M Diamond; Karen J Goodman; David P Paar
Journal:  Ann Epidemiol       Date:  2009-05-13       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.